@ZilliThomas

Radiation Oncology, IOSI - Oncology Institute of Southern Switzerland, EOC, Switzerland

 Bellinzona, Svizzera
Joined September 2018
  • Tweets2.9K
  • Following1K
  • Followers2K
66Media
Thomas Zilli retweeted
Enrique Grande
@drenriquegrande8h
PE-PE population: a new concept for oligonetastatic definition in RCC. Thanks @DrIacovelli for bringing up!!! Something that we were assuming and using in the clinic is now confirmed. Pembrolizumab should be offer as “adjuvant” treatment for oligometastatic PE-PE+ ccRCC patients. My question is; : what is the value/contribution of giving 1 cicle before SBRT/surgery? @myESMO @OncoAlert
7
21
1,009
Thomas Zilli retweeted
Alan Tan
@alantanmdOct 24
One year of APA+ADT comes with toxicity, and outcomes after control-arm salvage aren't shown. His view: follow-up too short; would not yet support perioperative APA+ADT with RP in high-risk disease, needing mature survival and post-salvage data first.
3
7
322
Thomas Zilli retweeted
Alfredo Addeo MD@Alfdoc26h
🚨 #ESMO26 | SARON: Better PFS, but NO overall survival benefit! @fifimcdrmh presents the randomized phase II SAFRON trial in synchronous oligometastatic, driver-negative NSCLC. 📊 Median OS: 🔹 SACT alone: 28.0 months 🔹 SACT + consolidative RT: 31.0 months 🔹 HR 0.99 (95% CI 0.63–1.55), p=0.95 ✅ Better disease control and longer PFS with RT. ❌ But NO OS benefit demonstrated! An important reminder: improving PFS does not necessarily translate into longer survival. Thought-provoking data challenging the routine use of consolidative RT in this setting! #ESMOAmbassadors #ESMO26 #LungCancer #NSCLC
3
6
300
Thomas Zilli retweeted
Zach Klaassen
@zklaassen_md20h
#ESMO26 DASL-HiCaP Presidential Discussant -- @Silke_Gillessen Differences in BL risk and pt selection may explain variation in treatment effects for STAMPEDE M0, ENZARAD, DASL-HiCaP Among N1 pts only, ARPI MFS benefit: ◾️STAMPEDE M0: HR 0.49, 95%CI 0.38-0.64 ◾️ENZARAD: HR 0.43, 95%CI 0.20-0.92 ◾️DASL-HiCaP: HR 0.39, 95%CI 0.19-0.81
1
20
41
1,654
Thomas Zilli retweeted
Shankar Siva
@_ShankarSivaOct 24
💥Game-changer in small cell #lungcancer! #ESMO26 LBA3 DeLLphi-305: Tarlatamab + durvalumab vs durvalumab 1L maintenance in ES-SCLC (n=563) after chemo-IO. Median OS ⬆️ 21.1 vs 12.7 mo (HR 0.42), PFS ⬆️7.4 vs 1.9 mo (HR 0.34), ORR 26% vs 4%. ☢️44% of pts still on T+D due to #radiotherapy of oligoprogressive sites? #SCLC #LCSM @NEJM ➡️ shorturl.at/IiOO1
1
18
2
52
2,044
Thomas Zilli retweeted
Toni Choueiri, MD
@DrChoueiriOct 23
Encouraging OS results in neuroendocrine prostate cancer at #ESMO26! #KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone. • mOS: 10.2 vs 7.1 months (HR 0.33) • rPFS: 5.1 vs 4.0 months (HR 0.66) • PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16) No new safety signals observed. @myESMO @oncoalert
2
50
3
110
6,389
With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer. ⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy. 🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it. #BladderCancer #GUOnc @OncoAlert @BladderCancerUS
4
42
83
3,546
Thomas Zilli retweeted
Zach Klaassen
@zklaassen_mdOct 24
Transcriptome classifier risk strat and intensification with ARPIs for clinically VHR PCa @urotoday #ESMO26 🚨STAMPEDE Abi trial (n=401); RWD cohort of NCCN high/very high risk PCa (n = 27,607) 🚨STAMPEDE - Decipher HR: ⏫DM, ⏬PCSS 🚨Decipher HR: Predictive of Abi benefit in STAMPEDE N0 pts (p-int: 0.01) 🚨Decipher: prognostic in RWD for DM, MFS, OS
15
1
16
994
Thomas Zilli retweeted
Toni Choueiri, MD
@DrChoueiriOct 24
Excellent presentation by Sarah Howlett! STAMPEDE biomarker analysis: higher Decipher scores predicted greater abiraterone benefit in preventing distant metastases in very high-risk M0 prostate cancer. A step toward smarter intensification! @myESMO #ESMO26 @oncoalert
14
1
20
1,392
Thomas Zilli retweeted
Toni Choueiri, MD
@DrChoueiriOct 24
Fantastic presentation by Karim Fizazi! PEACE-1 at 7.7 years: adding abiraterone to ADT + docetaxel improved median OS to 6.2 vs 4.4 years (HR 0.68) in de novo mCSPC. Durable benefit from upfront intensification! @myESMO #ESMO26 @oncoalert
32
2
75
3,716
Thomas Zilli retweeted
Dr Amol Akhade
@SuyogCancerOct 23
ESMO 2026 - presidential LBA | VOLGA Phase III – Perioperative Durvalumab + Enfortumab Vedotin (EV) in cisplatin-ineligible/refusing patients: 📊 EV + Durva vs Control • 2-year EFS: 64% vs 45% (HR 0.51; p<0.0001) • 2-year OS: 78% vs 69% (HR 0.58; p=0.0027) • pCR: 45% vs 10% Adding tremelimumab improved EFS (HR 0.61) but no significant OS benefit yet, with higher grade 3/4 toxicity (42% vs 30%). 🔥can this stop the need of post op EV ? Probably yes . New SOC 🙂👍 Looking forward the full datasets @OncBrothers @OncoAlert @myESMO #ESMO26 #VOLGA #BladderCancer
2
17
1
33
5,455
Thomas Zilli retweeted
Shankar Siva
@_ShankarSivaOct 23
🚨📣 big news at #ESMO26: 🧵1/MASTERPLAN RCT shows adding SABR to perioperative chemotherapy for high-risk localized #pancreatic cancer ⬆️⬆️ median overall survival to 22.0 months vs 14.0 months (HR 0.45). #PancreaticCancer #RadOnc @TROGfightcancer in press @TheLancetOncol - thelancet.com/journals/lanon…
5
80
4
152
7,797
Thomas Zilli retweeted
Tom Powles
@tompowles1Oct 23
It hard to explain why 1 trial with gem/cis +/-PD(L)1 (NIAGARA) is +ve for EFS/OS and 2 very similar trials (presented today) are negative in MIBC. Potentially NIAGARA has the highest risk population, not all respond to IO and the maintenance phase the most effect- but the OS of gem/cis pembro HR of 1 is concerning. This reflects what we saw in metastatic disease with contradictory results for the big combination trials. Overall EVP looks better and more consistent #ESMO26 @myESMO @Annals_Oncology @OncoAlert
4
69
5
175
10,227
⚡️ Phase 2 trial in RCC with inferior vena cava tumor thrombus: neoadjuvant stereotactic ablative radiotherapy (SAbR) followed by surgery (n=23). 1-year recurrence-free survival: 71.4% — above the 55.7% historical benchmark. Thrombus downstaging in 22%. A promising approach for one of the most challenging complications in kidney cancer. #KidneyCancer #RCC @JAMAOnc jamanetwork.com/journals/jam…
1
32
1
53
4,153
Excited to share our JAMA Oncology phase 2 trial of neoadjuvant SAbR for RCC with IVC tumor thrombus! 1-year RFS: 71.4%, meeting the prespecified criterion. Feasible with encouraging safety findings. Larger trials are next! doi.org/10.1001/jamaoncol.20… #KidneyCancer #RadOnc
3
18
54
2,813
Thomas Zilli retweeted
Alison Tree 💙@alison_treeSep 29
Replying to @DrSpratticus
Interesting data- penile bulb dose predicts ED in CHHiP, data from PACE-B will show association with crura D2% <12.7Gy, validating @Achard_Verane ‘s previous work (D2% <12Gy) . Prob all measuring the same thing.
1
4
16
609
Nice work! Study shows more RT fx > more lymphocyte depletion > worse OS. Palliative RT setting, but relevant to definitive/SBRT. Post-RT lymphocyte = underutilized biomarker IMO (though cheap, routinely collected) but increasingly important w more RT/IO integration. @OncoAlert
Leila Tchelebi@LeilaTchelebiOct 7
So proud of rockstar med student / future #RadOnc @JoshuaKimMSx on this important work on #palliative RT and #lymphopenia, now officially in press! #RT fractionation matters! @IJROBP Clinical and Treatment Factors associated with Lymphopenia after Palli… sciencedirect.com/science/ar…
19
2
47
4,175
Enjoyed this session & learned a lot! Both TARE & SBRT can deliver ablative RT in HCC. Key q is which approach is best suited for a given pt/tumor. Sharing some of my slides below re: decision-making b/w the 2 modalities. TY to @GIcancerDoc & @EileenMOReilly for the invite.
Dr. Nina Niu Sanford
@NiuSanfordSep 20
This should be a great meeting. Look forward to debating on SBRT vs. Y90 for HCC 🙂 Join us in Ft. Lauderdale or virtually 10/2-3!
1
41
84
6,147
Thomas Zilli retweeted
ASTRO
@ASTRO_orgOct 1
New in #practicalRO: Analysis of Major Joint Dosimetry Based on a Standardized Contouring Method Among Patients with Extremity Soft Tissue Sarcoma. This article was presented during #ASTRO2026 in Oral Scientific Session 24. bit.ly/46ODYbw
13
18
2,034
Thomas Zilli retweeted
Dr Najeed Aadil@daakhsaabSep 28
☢️ #ASTRO26: LDRT in knee OA is fascinating. 292 patients | 4.5 Gy/10 fractions At 3 years: 🦵 VAS pain: 21 vs 55 📈 Responders: 69% vs 25% (p<0.0001) Long-term: disability 14% vs 25%; KL-2 knee replacement 14% vs 36% (HR 0.32, p=0.021).
2
36
67
2,748
Load more